227 MET ECD shedding and use of targeted therapies 56. Benvenuti S, Gentile A, Lazzari L, Arnesano A, Trusolino L, Comoglio PM. An ‘in-cell trial’ to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. Mol Oncol 2014;8:378-88. 57. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73. 58. Madoz-Gurpide J, Zazo S, Chamizo C, Casado V, Carames C, Gavin E, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med 2015;13:282. 59. Hubel J, Hieronymus T. HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells. Biomedicines 2015;3:138-48. 60. Ilangumaran S, Villalobos-Hernandez A, Bobbala D, Ramanathan S. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway: Diverse roles in modulating immune cell functions. Cytokine 2016;82:125-39. 61. Wood GE, Hockings H, Hilton DM, Kermorgant S. The role of MET in chemotherapy resistance. Oncogene 2021;40:1927-41. 62. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011;13:827-37. 63. Hughes VS, Siemann DW. Have Clinical Trials Properly Assessed c-Met Inhibitors? Trends Cancer 2018;4:94-7. 64. Watermann I, Schmitt B, Stellmacher F, Muller J, Gaber R, Kugler C, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol 2015;10:130. 65. Copin MC, Lesaffre M, Berbon M, Doublet L, Leroy C, Tresch E, et al. High-MET status in non-small cell lung tumors correlates with receptor phosphorylation but not with the serum level of soluble form. Lung Cancer 2016;101:59-67. 7
RkJQdWJsaXNoZXIy MTk4NDMw